Patient Condition
The patient will experience significant memory decline in 2023, which will affect daily life. He visited Xuanwu Hospital and had an MMSE score of 16 (moderate AD). CSF examination supported the diagnosis of AD and was not suitable for monoclonal antibody treatment (older age).
Treatment Timeline
| Phase | Details | Date |
|---|
| Multi-dimensional evaluation and precise staging | | |
| Lecanemab anti-A β therapy +ARIA risk management | | |
| Remternetug (anti-tau antibody) combination therapy | | |
| Maintenance treatment and functional protection | | |
Treatment Outcome
| before | MMSE score 16, moderate cognitive impairment, need help in daily life |
|---|
| after | MMSE score 19 points (improvement by 3 points), cognitive function partially improved, and daily living ability improved |
|---|
| highlight | Drug combination treatment is effective and cognitive rehabilitation is well coordinated |
|---|